Pfizer has been ranked first in Australia/New Zealand for its corporate reputation, according to the 2022 PatientView survey, which examined 58 patient groups in Australia and New Zealand. PatientView’s Corporate Reputation of Pharma survey asks patient groups to assess pharma companies’ corporate reputation using 10 indicators, including patient centricity, information and safety, high-quality products, transparency, integrity, patientgroup relationships, services beyond the pill, involvement in R&D and equitable access. The 2022 survey includes eight ‘big pharma’ companies AbbVie, AstraZeneca, Bristol Myers Squibb, Gilead Sciences, Janssen, Novartis, Pfizer and Roche. “This achievement reflects our purpose to deliver breakthroughs that change patients’ lives,” said Anne Harris, Pfizer Australia & New Zealand Managing Director. “At Pfizer, patients are at the heart of our business decisions daily. “Understanding and acting on patients’ needs and expectations will help speed development and access to treatments. “As a result, every decision we make starts with the essential question – what will this mean for patients? “However, we are not resting on our laurels,” assured Harris. “We will place even greater focus on the inclusion of patients to enhance our understanding of patient needs and deliver decisions that serve them better.” According to Leigh-Anne Simmonds, Pfizer’s Senior Manager for Patient Advocacy, PatientView’s survey results speak to the commitment of all Pfizer colleagues to set a new standard in patient centricity. “We know patient centricity exists at Pfizer when we listen and learn from the patient perspective, acting as partners with accountability and integrity to deliver outcomes that matter most to patients and those involved in their care. “We do this through four key principles of patient-centricity insights and immersion, empowering and equipping, support and services, and advocacy action. “This is how we apply our patient focus every day,” Simmonds concluded.